CBS and prostate cancer: For example, serous ovarian cancer [32] as well as invasive urothelial bladder carcinoma [33], colorectal cancers [27] and prostate cancer [28] have shown high levels of CBS and inhibiting CBS has improved the effect of cisplatin-based chemotherapy in these neoplasms.